NIBEC Co.

NIBEC is established as a spin-off venture from Seoul National University, South Korea at 2004 and listed in Korean Stock Market (KOSDAQ) at 2011. The company's main technology is based on target-oriented peptide therapeutic discovery (TOPscovery) platform for drug discovery and development. NIBEC has target tissue/cell penetrating peptide delivery platform to deliver protein/antibody/siRNA into the target tissue such as cancer. The company's focus of therapeutic area are inflammatory diseases (NASH, IBD) and cancer with new mode of action. The other advanced therapeutic program is for the treatment of osteoporosis entering phase I. In addition to the drug development, the company holds medical device manufacturer license for tissue engineering biomaterials, tissue regenerative therapy dedicated to bone healing. The company has two research institutes and one manufacturing facility with fully granted GMP.